Article Information
History
- February 17, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Michal Podrazil, MD, PhD1,*,
- Pavla Taborska, PhD1,*,
- Dmitry Stakheev, MD, PhD1,*,
- Michal Rataj1,
- Jan Lastovicka, PhD1,
- Alena Vlachova, MD2,
- Petr Pohunek, MD, PhD3,
- Jirina Bartunkova, MD, PhD1 and
- Daniel Smrz, PhD1,†
- 1Department of Immunology, Second Faculty of Medicine, Charles University, and Motol University Hospital, Prague, Czech Republic
- 2Department of Pneumology, Second Faculty of Medicine, Charles University, and Motol University Hospital, Prague, Czech Republic
- 3Department of Pediatrics, Second Faculty of Medicine, Charles University, and Motol University Hospital, Prague, Czech Republic
- ↵†Address correspondence to Dr. Daniel Smrz: Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, V Uvalu 84, 150 06 Praha 5, Czech Republic; Phone: +420 224-43-5968; Fax: +420 224 435 962; E-mail: daniel.smrz{at}lfmotol.cuni.cz
Posted February 17, 2022.
Effectiveness and durability of the mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy
